GSK pursued the acquisition of Nuvalent to significantly bolster its oncology portfolio by securing two advanced, highly promising next-generation precision therapies targeting non-small cell lung cancer that were under active regulatory review. This strategic transaction added best-in-class brain-penetrant kinase inhibitors to GSK's pipeline, enabling the company to effectively compete against major pharmaceutical rivals in precision lung cancer care and accelerate its long-term specialty medicines growth strategy.